Clinical Trials Logo

MEK2 Gene Mutation clinical trials

View clinical trials related to MEK2 Gene Mutation.

Filter by:
  • None
  • Page 1

NCT ID: NCT05054374 Completed - Breast Cancer Clinical Trials

A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

Start date: September 14, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study to find out whether mirdametinib is a safe treatment for people with advanced solid tumor cancer that has certain mutations. Researchers will look at whether mirdametinib on its own or in combination with the drug fulvestrant is a safe treatment that causes few or mild side effects in people with advanced solid tumor cancer.

NCT ID: NCT04534283 Terminated - Cancer Clinical Trials

A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

Start date: October 5, 2020
Phase: Phase 2
Study type: Interventional

The purpose of CTO-IUSCC-0730 study is to assess the clinical efficacy of LY3214996 in combination with abemaciclib at the recommended phase 2 dose of LY3214996 200 mg orally daily and abemaciclib 150 mg orally twice daily. Patients will be treated until evidence of disease progression, non-compliance with study protocol, unacceptable major toxicity, at subject's own request for withdrawal, or if the study closes for any reason.